Fig. 1

Significant events during establishment of the COVID-19 perinatal biorepository impacting cumulative enrollment of pregnant women over time. a. Timeline of events impacting enrollment of pregnant women into the biorepository. b. Blue line indicates cumulative enrollment of COV19+ pregnant women. Black line indicates cumulative number of all enrolled pregnant women (COV19+ and COV19-). Phase 1 of enrollment is defined as April 2 to May 4, prior to interventions streamlining enrollment including (1) unification of Obstetrics and Neonatology teams, allowing enrollment into maternal and newborn protocols at the same time and (2) expansion of enrollment efforts to non-hospitalized women. Phase 2 is defined as May 4 to June 9. MGH = Massachusetts General Hospital. COV19+ = mother positive for SARS-CoV-2 on RT-PCR of nasopharyngeal swab at any time during pregnancy; COV19- = mother negative for SARS-CoV-2 on RT-PCR of nasopharyngeal swab when tested for COVID-19 symptoms or as part of universal screening protocol